BRAIN-2 COVID-19 Administrative Supplement

美国国立卫生研究院资助的BRAIN-ICU-2研究揭示了神经心理疾病的危险因素和发病率 ICU幸存者的功能障碍（痴呆），第2次研究]将定义ICU谵妄与 痴呆BRAIN-ICU-2研究（R 01 AG 58639）的拟议行政补充是对以下内容的回应 NIA关于冠状病毒疾病的行政补充和修订补充的可用性2019 （COVID-19）（NOT-AG-022; PA-18-591）。目的：了解急性谵妄的脑组织损害， 严重急性呼吸道综合征冠状病毒-2（SARS-CoV-2），我们将进行新的神经病理学检查， 对受COVID-19影响的重症患者以及阿尔茨海默病和相关疾病患者的研究 痴呆（ADRD）伴/不伴危重病。通过研究COVID-19，我们将更好地了解 精神错乱和ADRD之间的区别在当前的COVID-19大流行期间，全世界的重症监护病房（ICU） 全国都充斥着经历谵妄的患者，这是未来ADRD的主要ICU风险因素。这些谵妄 意识受损的症状包括头痛，味觉、嗅觉和视觉功能的改变， 神经病、癫痫、激越、脑炎和/或格林-巴利综合征。这些精神错乱的症状 症状可能是由于SARS-CoV-2感染大脑，特别是在ADRD患者中。我们不 了解COVID-19是否会对神经系统产生直接影响（例如，炎症），和/或间接 神经系统后果，例如，凝血病据我们所知，有限的尸检系列，包括 脑组织已经发表。未提供关于ADRD的信息。拟议的补编将 具体比较多组患者，ICU患者伴/不伴ADRD伴/不伴COVID-19，沿着 非ICU患者，伴/不伴ADRD和伴/不伴COVID-19。BRAIN-ICU-2研究将提供ICU 有/无ADRD伴/不伴COVID-19的患者。国家情报局支持的宗教秩序研究（ROS; P30 AG 10161，R 01 AG 15819）和Rush记忆和老化项目（MAP; R 01 AG 17917）将提供非ICU 有/无ADRD和有/无COVID-19的患者。拟议的补充将进一步发展 这是范德比尔特和拉什BRAIN-ICU-2研究团队之间的合作，代表了 与非COVID-19大脑相比，对COVID-19大脑进行全面的神经病理学检查， 有/无ADRD，有/无危重疾病。这一补充将创造一个独特的资源 全球COVID-19研究界，对ICU谵妄领域产生了强大而持续的影响 和ADRD。

The NIA-funded BRAIN-ICU-2 Study [Bringing to light the Risk factors And Incidence of Neuropsychological dysfunction (dementia) in ICU Survivors, 2nd Study] will define the relationship between ICU delirium and dementia. The proposed administrative supplement to BRAIN-ICU-2 Study (R01 AG58639) is in response to NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-AG-022; PA-18-591). To understand the brain tissue damage of acute delirium caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), we will perform new neuropathological studies of critically ill patients affected by COVID-19, as well as those with Alzheimer’s disease and related dementia (ADRD) with/without critical illness. By studying COVID-19, we will better understand the relationship between delirium and ADRD. During the current COVID-19 pandemic, intensive care units (ICU’s) across the nation are awash with patients experiencing delirium, a major ICU risk factor for future ADRD. These delirium symptoms of impaired consciousness include headache, alteration of gustatory, olfactory, and visual function, neuropathy, seizures, agitation, encephalitis, and/or Guillain-Barre syndrome. These delirium signs and symptoms could be due to SARS-CoV-2 infection of the brain, particularly in those with ADRD. We do not know if there are direct nervous system consequences of COVID-19 (e.g., inflammation), and/or indirect nervous system consequences, e.g., coagulopathy. To our knowledge, limited autopsy series that included brain tissue have been published. No information about ADRD was provided. The proposed supplement will specifically compare multiple groups of patients, ICU patients with/without ADRD with/without COVID-19, along with non-ICU patients with/without ADRD and with/without COVID-19. The BRAIN-ICU-2 study will provide ICU patients with/without ADRD with/without COVID-19. The NIA-supported Religious Orders Study (ROS; P30 AG10161, R01 AG15819), and Rush Memory and Aging Project (MAP; R01 AG17917) will provide non-ICU patients with/without ADRD and with/without COVID-19. The proposed supplement will further build on collaboration between the Vanderbilt and Rush BRAIN-ICU-2 study teams, and represent the most comprehensive neuropathologic examination of COVID-19 brains compared to non-COVID-19 brains, in those with/without ADRD, and with/without critical illness. This supplement will create a unique resource for the world-wide COVID-19 research community, with a strong and sustained impact on the fields of ICU delirium and ADRD.